Abstract
Background: As is well-known, serotonin-reuptake inhibitors (SRIs) are unsuccessful in management of forty to sixty percent of patients suffering from obsessivecompulsive disorder (OCD). So, purpose of the present trial was to assess that whether addon aripiprazole, as adjunctive to SRIs, is helpful in cases with treatment-resistant OCD.
Method: In an Open-prospective, single-arm interventional study with blinded rating, sixteen patients with OCD, who had not improved noticeably by serotonin-reuptake inhibitors, after maximum dosage and period, were allocated to get aripiprazole plus their SRIs for eight weeks. Management outcome was measured by means of the Yale-Brown Obsessive Compulsive Scale (YBOCS). Complete reaction to the abovementioned augmentative therapy was demarcated of at least fifty percent reduction in YBOCS’ score and partial reaction as equivalent to or >25% - <50% reduction in YBOCS in comparison with the starting point.
Results: Neither of patients responded with at least 25% decrease in YBOCS score to the aripiprazole addition (20 mg/day). 18% of cases experienced a reduction between 10-20%, and 68% of them less than 10%. Two patients did not show any change at all. The mean+/-SD baseline YBOCS’ score of 35.2 +/- 2.9 dropped to a mean of 32.8 +/- 4.1 at endpoint with a mean reduction of 8.8+/- 7.8% (p<0.06).
Conclusion: Within the limits of statistical power, this assessment does not offer additional proof that adding of aripiprazole to current SRI treatment could be worthwhile for cases suffering from treatment-resistant OCD.
Keywords: Antipsychotic, aripiprazole, obsessive-compulsive disorder, treatment resistant.
Current Psychopharmacology
Title:Aripiprazole Addition to Serotonin Reuptake Inhibitor in Treatment-Resistant Obsessive-Compulsive Disorder
Volume: 3
Author(s): Saeed Shoja Shafti
Affiliation:
Keywords: Antipsychotic, aripiprazole, obsessive-compulsive disorder, treatment resistant.
Abstract: Background: As is well-known, serotonin-reuptake inhibitors (SRIs) are unsuccessful in management of forty to sixty percent of patients suffering from obsessivecompulsive disorder (OCD). So, purpose of the present trial was to assess that whether addon aripiprazole, as adjunctive to SRIs, is helpful in cases with treatment-resistant OCD.
Method: In an Open-prospective, single-arm interventional study with blinded rating, sixteen patients with OCD, who had not improved noticeably by serotonin-reuptake inhibitors, after maximum dosage and period, were allocated to get aripiprazole plus their SRIs for eight weeks. Management outcome was measured by means of the Yale-Brown Obsessive Compulsive Scale (YBOCS). Complete reaction to the abovementioned augmentative therapy was demarcated of at least fifty percent reduction in YBOCS’ score and partial reaction as equivalent to or >25% - <50% reduction in YBOCS in comparison with the starting point.
Results: Neither of patients responded with at least 25% decrease in YBOCS score to the aripiprazole addition (20 mg/day). 18% of cases experienced a reduction between 10-20%, and 68% of them less than 10%. Two patients did not show any change at all. The mean+/-SD baseline YBOCS’ score of 35.2 +/- 2.9 dropped to a mean of 32.8 +/- 4.1 at endpoint with a mean reduction of 8.8+/- 7.8% (p<0.06).
Conclusion: Within the limits of statistical power, this assessment does not offer additional proof that adding of aripiprazole to current SRI treatment could be worthwhile for cases suffering from treatment-resistant OCD.
Export Options
About this article
Cite this article as:
Shoja Shafti Saeed, Aripiprazole Addition to Serotonin Reuptake Inhibitor in Treatment-Resistant Obsessive-Compulsive Disorder, Current Psychopharmacology 2014; 3 (3) . https://dx.doi.org/10.2174/221155600303150629162749
DOI https://dx.doi.org/10.2174/221155600303150629162749 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cognitive Event-Related Potentials: Useful Clinical Information in Alzheimers Disease
Current Alzheimer Research Social Justice and HIV Vaccine Research in the Age of Pre-Exposure Prophylaxis and Treatment as Prevention
Current HIV Research Cucurbituril Complexes of Redox Active Guests
Current Organic Chemistry Navigating Alzheimer’s Disease via Chronic Stress: The Role of Glucocorticoids
Current Drug Targets Targeting the Alpha 7 Nicotinic Acetylcholine Receptor to Reduce Amyloid Accumulation in Alzheimers Disease Pyramidal Neurons
Current Pharmaceutical Design Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes
Current Pharmaceutical Design Universal Nature of Spondyloarthropathy as a Reactive Disease, Reflecting Differential Sensitivities
Current Rheumatology Reviews Congenital Heart Disease: The Crossroads of Genetics, Epigenetics and Environment
Current Genomics Update of QSAR & Docking & Alignment Studies of the DNA Polymerase Inhibitors
Current Bioinformatics Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry The Pleiotropic Effects of PPARs on Vascular Cells and Angiogenesis: Implications for Tissue Engineering
Current Stem Cell Research & Therapy Characterization of Graphs for Protein Structure Modeling and Recognition of Solubility
Current Bioinformatics Apolipoprotein E Gene Revisited: Contribution of Rare Variants to Alzheimer’s Disease Susceptibility in Southern Chinese
Current Alzheimer Research Managing Neuropathic Pain in Multiple Sclerosis: Pharmacological Interventions
Medicinal Chemistry MR Spectroscopy Findings of the Basal Ganglia in Bipolar Disorders: a Systematic Review
Current Psychiatry Reviews Role of Prostaglandins in Multiple Sclerosis
Current Pharmaceutical Design Prescription Opioid Abuse and its Potential Role in Gross Dental Decay
Current Drug Safety Molecular Modeling of Benzimidazole Derivatives: A Promising Series of GluN2B Selective NMDA Receptor Antagonists
Current Drug Therapy Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness
Current Neuropharmacology Role of Dimerization in Dopamine D<sub>4</sub> Receptor Biogenesis
Current Protein & Peptide Science